{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-127337","form_type":"8-K","ticker":"HOOK","cik":"0001760542","company_name":"HOOKIPA Pharma Inc.","filed_at":"2022-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.015173+00:00","generated_at":"2026-06-21T04:14:42.248542+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"HOOKIPA appoints Katia Schlienger as CMO and Malte Peters to board effective Jan 1, 2023","bullets":["Katia Schlienger promoted to CMO effective Jan 1, 2023; previously EVP Clinical R&D since July 2022.","Malte Peters appointed to Board of Directors effective Jan 1, 2023; retiring as MorphoSys Chief R&D Officer at end of 2022.","Schlienger spent 14 years at Merck & Co. in oncology and vaccine development.","Peters previously held leadership roles at Novartis Oncology, Sandoz, and Micromet; also on Tango Therapeutics board.","Peters receives initial option for 19,200 shares, $40k annual cash retainer, and stock awards per non-employee director policy."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-127337","json":"https://secwatch.observer/filing/0001104659-22-127337.json","markdown":"https://secwatch.observer/filing/0001104659-22-127337.md","text":"https://secwatch.observer/filing/0001104659-22-127337.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760542/000110465922127337/0001104659-22-127337-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760542/000110465922127337/tm2232803d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T04:14:42.248542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b23fddd35f","claim":"Malte Peters was appointed as Director at HOOKIPA Pharma Inc..","evidence_excerpt":"On December 9, 2022, the Board of Directors (the “Board”) of HOOKIPA Pharma Inc. (the Company”) appointed Malte Peters, M.D. as a director of the Board, effective January 1, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1760542/000110465922127337/0001104659-22-127337-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}